Akebia CAO Violetta Cotreau to resign; CFO David Spellman named principal accounting officer

Akebia Therapeutics, Inc.

Violetta Cotreau resigns as Chief Accounting Officer, effective Dec 30, 2022, to pursue new career opportunity.
David A. Spellman, currently CFO, appointed as principal accounting officer effective Dec 30, 2022.
Spellman has over two decades of biopharma finance experience; previously at Vertex, Intarcia, and Mersana.
Spellman will continue as CFO and Treasurer in addition to the principal accounting officer role.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Violetta Cotreau

Chief Accounting Officer

AKBA · Akebia Therapeutics, Inc.

Effective: 2022-12-30
Successor: David A. Spellman
Filed: December 15, 2022, 6:59 PM ET

On December 14, 2022, Violetta Cotreau, Chief Accounting Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of her intent to resign to pursue a new career opportunity.

Appointed

David A. Spellman

principal accounting officer

AKBA · Akebia Therapeutics, Inc.

Effective: 2022-12-30
Filed: December 15, 2022, 6:59 PM ET

The Board of Directors of the Company has appointed David A. Spellman, the Company’s Chief Financial Officer, as principal accounting officer, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Violetta Cotreau resigned as Chief Accounting Officer at Akebia Therapeutics, Inc..

Action: resigned
Role: Chief Accounting Officer

Exact text from the filing

On December 14, 2022, Violetta Cotreau, Chief Accounting Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of her intent to resign to pursue a new career opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David A. Spellman was appointed as principal accounting officer at Akebia Therapeutics, Inc..

Action: appointed
Role: principal accounting officer

Exact text from the filing

The Board of Directors of the Company has appointed David A. Spellman, the Company’s Chief Financial Officer, as principal accounting officer, effective as of the Effective Date.

View on SEC.gov

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-305886

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.